Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Abstract: Antibody–drug conjugates (ADCs) are a growing class of therapeutics that harness the specificity of antibodies and the cell‐killing potency of small‐molecule drugs. Beyond cytotoxics, there are few examples of the application of an ADC approach to difficult drug discovery targets. Here, we present the initial development of a non‐internalising ADC, with a view to selectively inhibiting an extracellular protein. Employing the wellinvestigated matrix metalloproteinase‐9 (MMP‐9) as our model, we adapted a broad‐spectrum, nonselective MMP inhibitor for conjugation and linked this to a MMP‐9‐targeting antibody. The resulting ADC fully inhibits MMP‐9, and ELISA results suggest antibody targeting can direct a nonselective inhibitor.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein ; volume:20 ; number:6 ; year:2019 ; pages:754-758 ; extent:5
ChemBioChem ; 20, Heft 6 (2019), 754-758 (gesamt 5)
- Urheber
-
Love, Elizabeth A.
Sattikar, Afrah
Cook, Hannah
Gillen, Kevin
Large, Jonathan M.
Patel, Seema
Matthews, David
Merritt, Andy
- DOI
-
10.1002/cbic.201800623
- URN
-
urn:nbn:de:101:1-2022081106284539546104
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Love, Elizabeth A.
- Sattikar, Afrah
- Cook, Hannah
- Gillen, Kevin
- Large, Jonathan M.
- Patel, Seema
- Matthews, David
- Merritt, Andy
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin